Document Detail


Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis.
MedLine Citation:
PMID:  18084757     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: Despite accumulating reports on the clinical value of (18)F-fluoro-2-deoxyglucose positron emission tomography (18F-FDG PET) and magnetic resonance imaging (MRI) in the assessment of cardiac sarcoidosis, no studies have systematically compared the images of these modalities. METHODS: Twenty-one consecutive patients with suspected cardiac sarcoidosis underwent cardiac examinations that included 18F-FDG PET and MRI. The association of 18F-FDG PET and MRI findings with blood sampling data such as serum angiotensin converting enzyme levels was also evaluated. RESULTS: Eight of 21 patients were diagnosed as having cardiac sarcoidosis according to the Japanese Ministry of Health and Welfare Guidelines for Diagnosing Cardiac Sarcoidosis. Sensitivity and specificity for diagnosing cardiac sarcoidosis were 87.5 and 38.5%, respectively, for 18F-FDG PET, and 75 and 76.9%, respectively, for MRI. When the 18F-FDG PET and MRI images were compared, 16 of 21 patients showed positive findings in one (n = 8) or both (n = 8) of the two modalities. In eight patients with positive findings on both images, the distribution of the findings differed among all eight cases. The presence of positive findings on 18F-FDG PET was associated with elevated serum angiotensin-converting enzyme levels; this association was not demonstrated on MRI. CONCLUSIONS: Both 18F-FDG PET and MRI provided high sensitivity for diagnosing cardiac sarcoidosis in patients with suspected cardiac involvement, but the specificity of (18)F-FDG PET was not as high as previously reported. The different distributions of the findings in the two modalities suggest the potential of 18F-FDG PET and MRI in detecting different pathological processes in the heart.
Authors:
Hiroshi Ohira; Ichizo Tsujino; Shinji Ishimaru; Noriko Oyama; Toshiki Takei; Eriko Tsukamoto; Masatake Miura; Shinji Sakaue; Nagara Tamaki; Masaharu Nishimura
Related Documents :
6334107 - A new headholder for pet, ct, and nmr imaging.
20514387 - Lesion concordance, image quality and artefacts in pet/ct: results of a multicenter study.
9831467 - Metabolic rate in the right amygdala predicts negative affect in depressed patients.
8940707 - A review of new oncotropic tracers for pet imaging.
16705997 - Enhancing the utility of prostascint spect scans for patient management.
2352637 - Primary choroid plexus papilloma of the cerebellopontine angle: mr imaging.
Publication Detail:
Type:  Journal Article     Date:  2007-12-15
Journal Detail:
Title:  European journal of nuclear medicine and molecular imaging     Volume:  35     ISSN:  1619-7070     ISO Abbreviation:  Eur. J. Nucl. Med. Mol. Imaging     Publication Date:  2008 May 
Date Detail:
Created Date:  2008-04-14     Completed Date:  2008-08-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101140988     Medline TA:  Eur J Nucl Med Mol Imaging     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  933-41     Citation Subset:  IM    
Affiliation:
First Department of Medicine, Hokkaido University School of Medicine, N15, W7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Cardiomyopathies / diagnosis*
Female
Fluorodeoxyglucose F18 / diagnostic use*
Humans
Image Enhancement / methods
Magnetic Resonance Imaging / methods*
Male
Middle Aged
Positron-Emission Tomography / methods*
Radiopharmaceuticals / diagnostic use
Reproducibility of Results
Sarcoidosis / diagnosis*
Sensitivity and Specificity
Subtraction Technique
Chemical
Reg. No./Substance:
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Properties and applications of microbial D-amino acid oxidases: current state and perspectives.
Next Document:  An 8- to 10-year review of the Rotaglide total knee replacement.